Pillar 3 - AML, page-114

Dosing of 3 patients in the cohort could theoretically be simultaneously. Reality is patients recruited into the trial need to match the eligibility criteria, the doctor needs to suggest enrolment into the trial and the patient (likely with input from their family) need agree to participate in the trial.

That's multiple gates for a patient to get through before they can be dosed. Also there is the reality that it may take time for a patient that sufficiently matches the eligibility criteria is identified. The lag between one and the next patient being dosed could be weeks/months.

Whilst the dosing of 3 patients could be theoretically done simultaneously the practicalities mean that is unlikely.

It does help that the history of Bisantrene from the 1980s/90s is known.

There has also been speculation (by from memory @Titans19) that this new combination may have already been tried in a compassionate use setting.